Last 12 months
Inside the activity.
0 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2023 Filed Jun 14, 2023 20:53 UTC |
Ryan ReneeDirector
|
GrantStock Option (Rt to Buy) · Derivative | 27,380 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001209191-23-037072 · doc4.xml · derivative · entry 1 Ryan Renee · CIK 0001855576 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,380 Underlying: Common Stock · 27,380 shares Expires 2033-06-06 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| June 07, 2023 Filed Jun 14, 2023 20:58 UTC |
Geiger UriDirector
|
GrantStock Option (Rt to Buy) · Derivative | 27,380 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001209191-23-037075 · doc4.xml · derivative · entry 1 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,380 Underlying: Common Stock · 27,380 shares Expires 2033-06-06 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| June 07, 2023 Filed Jun 14, 2023 20:59 UTC |
Fischer Frank MDirector
|
GrantStock Option (Rt to Buy) · Derivative | 27,380 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001209191-23-037077 · doc4.xml · derivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,380 Underlying: Common Stock · 27,380 shares Expires 2033-06-06 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| June 07, 2023 Filed Jun 14, 2023 20:54 UTC |
LACOB JOSEPHDirector
|
GrantStock Option (Rt to Buy) · Derivative | 27,380 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001209191-23-037073 · doc4.xml · derivative · entry 1 LACOB JOSEPH · CIK 0001215490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,380 Underlying: Common Stock · 27,380 shares Expires 2033-06-06 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| June 07, 2023 Filed Jun 14, 2023 21:00 UTC |
Andrade LisaDirector
|
GrantStock Option (Rt to Buy) · Derivative | 27,380 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001209191-23-037078 · doc4.xml · derivative · entry 1 Andrade Lisa · CIK 0001595202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,380 Underlying: Common Stock · 27,380 shares Expires 2033-06-06 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| June 07, 2023 Filed Jun 14, 2023 20:56 UTC |
Kumar RakhiDirector
|
GrantStock Option (Rt to Buy) · Derivative | 27,380 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001209191-23-037074 · doc4.xml · derivative · entry 1 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,380 Underlying: Common Stock · 27,380 shares Expires 2033-06-06 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| June 03, 2023 Filed Feb 25, 2025 23:31 UTC |
Morrell MarthaCHIEF MEDICAL OFFICER
|
Tax withholdingCommon Stock | 1,303 | $4.11 | $5,355.33 |
DisclosureSEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 7 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,407 Read SEC document |
| June 03, 2023 Filed Feb 25, 2025 17:41 UTC |
Kuhn RebeccaChief Financial Officer
|
Tax withholdingCommon Stock | 1,010 | $4.11 | $4,151.10 |
DisclosureSEC source: 0001415889-25-005559 · form4-02252025_100218.xml · nonDerivative · entry 7 Kuhn Rebecca · CIK 0001855659 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,706 Read SEC document |
| April 22, 2023 Filed Feb 25, 2025 23:31 UTC |
Morrell MarthaCHIEF MEDICAL OFFICER
|
Tax withholdingCommon Stock | 231 | $4.25 | $981.75 |
DisclosureSEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 6 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,710 Read SEC document |
| April 22, 2023 Filed Feb 25, 2025 17:41 UTC |
Kuhn RebeccaChief Financial Officer
|
Tax withholdingCommon Stock | 179 | $4.25 | $760.75 |
DisclosureSEC source: 0001415889-25-005559 · form4-02252025_100218.xml · nonDerivative · entry 6 Kuhn Rebecca · CIK 0001855659 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,716 Read SEC document |
| March 03, 2023 Filed Feb 25, 2025 23:31 UTC |
Morrell MarthaCHIEF MEDICAL OFFICER
|
Tax withholdingCommon Stock | 5,167 | $4.10 | $21,184.70 |
DisclosureSEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 5 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,941 Read SEC document |
| March 03, 2023 Filed Feb 25, 2025 17:41 UTC |
Kuhn RebeccaChief Financial Officer
|
Tax withholdingCommon Stock | 4,019 | $4.10 | $16,477.90 |
DisclosureSEC source: 0001415889-25-005559 · form4-02252025_100218.xml · nonDerivative · entry 5 Kuhn Rebecca · CIK 0001855659 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,895 Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 19:38 UTC |
Favet MichaelDirector · Chief Executive Officer
|
GrantCommon Stock | 225,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011945 · doc4.xml · nonDerivative · entry 1 Favet Michael · CIK 0001855656 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,080 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on February 21, 2024 and the remaining RSUs vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 20, 2023 Filed Feb 22, 2023 19:54 UTC |
Ridley IrinaChief Legal Officer/Secretary
|
GrantCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011968 · doc4.xml · nonDerivative · entry 1 Ridley Irina · CIK 0001855591 · Chief Legal Officer/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,139 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on February 20, 2024 and the remaining RSUs vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 20, 2023 Filed Feb 23, 2023 00:39 UTC |
Morrell MarthaChief Medical Officer
|
GrantCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011946 · doc4.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,164 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on February 20, 2024 and the remaining RSUs vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 20, 2023 Filed Feb 22, 2023 19:53 UTC |
Kuhn RebeccaChief Financial Officer
|
GrantCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011965 · doc4.xml · nonDerivative · entry 1 Kuhn Rebecca · CIK 0001855659 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,704 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on February 20, 2024 and the remaining RSUs vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| January 22, 2023 Filed Feb 25, 2025 23:31 UTC |
Morrell MarthaCHIEF MEDICAL OFFICER
|
Tax withholdingCommon Stock | 264 | $2.98 | $786.72 |
DisclosureSEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 4 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,108 Read SEC document |
| January 22, 2023 Filed Feb 25, 2025 17:41 UTC |
Kuhn RebeccaChief Financial Officer
|
Tax withholdingCommon Stock | 212 | $2.98 | $631.76 |
DisclosureSEC source: 0001415889-25-005559 · form4-02252025_100218.xml · nonDerivative · entry 4 Kuhn Rebecca · CIK 0001855659 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,914 Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:30 UTC |
Geiger UriDirector
|
GrantStock Option (Right to Buy) · Derivative | 120,521 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001209191-23-002565 · doc4.xml · derivative · entry 1 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,521 Underlying: Common Stock · 120,521 shares Expires 2033-01-04 F1 · derivative.exercise_date: The shares subject to the option shall vest in thirty six (36) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 17:29 UTC |
Accelmed Partners II L.P.10% owner
|
PurchaseCommon Stock | 62,398 | $1.50 | $93,534.60 |
DisclosureSEC source: 0000899243-22-036949 · doc4.xml · nonDerivative · entry 2 Accelmed Partners II L.P. · CIK 0001807256 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,432,948 Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 17:29 UTC |
Accelmed Partners II L.P.10% owner
|
PurchaseCommon Stock | 327,893 | $1.50 | $491,511.61 |
DisclosureSEC source: 0000899243-22-036949 · doc4.xml · nonDerivative · entry 1 Accelmed Partners II L.P. · CIK 0001807256 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,370,550 F1 · ownership.direct: Shares are held by Accelmed Partners II LP. Accelmed Partners II, LLC ("Accelmed LLC") is the general partner of Accelmed Partners II GP, L.P., which is the general partner of Accelmed Partners II LP. Uri Geiger is the managing partner of Accelmed LLC and has sole voting and dispositive power with respect to the shares held by Accelmed Partners II LP. Dr. Uri Geiger is the Managing Partner of Accelmed LLC. The address of each of Accelmed Partners II GP, LP and Accelmed Partners II LP is Ugland House, South Church Street, PO Box 309, Grand Cayman KY1-1104, Cayman Islands. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 21:18 UTC |
Kuhn RebeccaChief Financial Officer
|
Exercise / conversionStock Option (Rt to Buy) · Derivative | 482 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001209191-22-055434 · doc4.xml · derivative · entry 6 Kuhn Rebecca · CIK 0001855659 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 482 shares Expires 2025-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The share underlying the option are fully vested. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 21:18 UTC |
Kuhn RebeccaChief Financial Officer
|
Exercise / conversionStock Option (Rt to Buy) · Derivative | 254 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001209191-22-055434 · doc4.xml · derivative · entry 5 Kuhn Rebecca · CIK 0001855659 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 254 shares Expires 2024-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The share underlying the option are fully vested. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 21:18 UTC |
Kuhn RebeccaChief Financial Officer
|
Exercise / conversionStock Option (Rt to Buy) · Derivative | 692 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001209191-22-055434 · doc4.xml · derivative · entry 4 Kuhn Rebecca · CIK 0001855659 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 692 shares Expires 2022-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The share underlying the option are fully vested. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 21:18 UTC |
Kuhn RebeccaChief Financial Officer
|
Exercise / conversionCommon Stock | 482 | $0.03 | $12.53 |
DisclosureSEC source: 0001209191-22-055434 · doc4.xml · nonDerivative · entry 3 Kuhn Rebecca · CIK 0001855659 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 21:18 UTC |
Kuhn RebeccaChief Financial Officer
|
Exercise / conversionCommon Stock | 254 | $0.03 | $6.60 |
DisclosureSEC source: 0001209191-22-055434 · doc4.xml · nonDerivative · entry 2 Kuhn Rebecca · CIK 0001855659 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 21:18 UTC |
Kuhn RebeccaChief Financial Officer
|
Exercise / conversionCommon Stock | 692 | $0.03 | $17.99 |
DisclosureSEC source: 0001209191-22-055434 · doc4.xml · nonDerivative · entry 1 Kuhn Rebecca · CIK 0001855659 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 22, 2022 Filed Feb 25, 2025 23:31 UTC |
Morrell MarthaCHIEF MEDICAL OFFICER
|
Tax withholdingCommon Stock | 233 | $3.02 | $703.66 |
DisclosureSEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 3 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,372 Read SEC document |
| October 22, 2022 Filed Feb 25, 2025 17:41 UTC |
Kuhn RebeccaChief Financial Officer
|
Tax withholdingCommon Stock | 181 | $3.02 | $546.62 |
DisclosureSEC source: 0001415889-25-005559 · form4-02252025_100218.xml · nonDerivative · entry 3 Kuhn Rebecca · CIK 0001855659 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,126 Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 23:57 UTC |
LACOB JOSEPHDirector
|
Exercise / conversionStock Option (Rt to Buy) · Derivative | 192 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001209191-22-054222 · doc4.xml · derivative · entry 3 LACOB JOSEPH · CIK 0001215490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 192 shares Expires 2022-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The share underlying the option are fully vested. Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 23:57 UTC |
LACOB JOSEPHDirector
|
Exercise / conversionCommon Stock | 192 | $0.03 | $4.99 |
DisclosureSEC source: 0001209191-22-054222 · doc4.xml · nonDerivative · entry 1 LACOB JOSEPH · CIK 0001215490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2022 Filed Oct 11, 2022 20:09 UTC |
Morrell MarthaChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 384 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001209191-22-053273 · doc4.xml · derivative · entry 4 Morrell Martha · CIK 0001855616 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 384 shares Expires 2023-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying the option are fully vested. Read SEC document |
| October 07, 2022 Filed Oct 11, 2022 20:09 UTC |
Morrell MarthaChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 192 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001209191-22-053273 · doc4.xml · derivative · entry 3 Morrell Martha · CIK 0001855616 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 192 shares Expires 2022-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying the option are fully vested. Read SEC document |
| October 07, 2022 Filed Oct 11, 2022 20:09 UTC |
Morrell MarthaChief Medical Officer
|
Exercise / conversionCommon Stock | 384 | $0.03 | $9.98 |
DisclosureSEC source: 0001209191-22-053273 · doc4.xml · nonDerivative · entry 2 Morrell Martha · CIK 0001855616 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2022 Filed Oct 11, 2022 20:09 UTC |
Morrell MarthaChief Medical Officer
|
Exercise / conversionCommon Stock | 192 | $0.03 | $4.99 |
DisclosureSEC source: 0001209191-22-053273 · doc4.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 22, 2022 Filed Feb 25, 2025 23:31 UTC |
Morrell MarthaCHIEF MEDICAL OFFICER
|
Tax withholdingCommon Stock | 231 | $5.55 | $1,282.05 |
DisclosureSEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 2 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,605 Read SEC document |
| July 22, 2022 Filed Feb 25, 2025 17:41 UTC |
Kuhn RebeccaChief Financial Officer
|
Tax withholdingCommon Stock | 179 | $5.55 | $993.45 |
DisclosureSEC source: 0001415889-25-005559 · form4-02252025_100218.xml · nonDerivative · entry 2 Kuhn Rebecca · CIK 0001855659 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,307 Read SEC document |
| June 13, 2022 Filed Jun 22, 2022 01:09 UTC |
Ryan ReneeDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,253 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001209191-22-038604 · doc4.xml · derivative · entry 1 Ryan Renee · CIK 0001855576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,253 Underlying: Common Stock · 18,253 shares Expires 2032-06-12 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| June 13, 2022 Filed Jun 22, 2022 01:12 UTC |
Fischer Frank MDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,253 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001209191-22-038614 · doc4.xml · derivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,253 Underlying: Common Stock · 18,253 shares Expires 2032-06-12 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| June 13, 2022 Filed Jun 22, 2022 01:10 UTC |
LACOB JOSEPHDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,253 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001209191-22-038607 · doc4.xml · derivative · entry 1 LACOB JOSEPH · CIK 0001215490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,253 Underlying: Common Stock · 18,253 shares Expires 2032-06-12 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| June 13, 2022 Filed Jun 22, 2022 01:13 UTC |
Andrade LisaDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,253 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001209191-22-038617 · doc4.xml · derivative · entry 1 Andrade Lisa · CIK 0001595202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,253 Underlying: Common Stock · 18,253 shares Expires 2032-06-12 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| June 13, 2022 Filed Jun 22, 2022 01:11 UTC |
Kumar RakhiDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,253 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001209191-22-038610 · doc4.xml · derivative · entry 1 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,253 Underlying: Common Stock · 18,253 shares Expires 2032-06-12 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| June 13, 2022 Filed Jun 22, 2022 01:12 UTC |
Garfield Greg ShawDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,253 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001209191-22-038612 · doc4.xml · derivative · entry 1 Garfield Greg Shaw · CIK 0001594406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,253 Underlying: Common Stock · 18,253 shares Expires 2032-06-12 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 19:47 UTC |
Ridley IrinaGeneral Counsel and Secretary
|
SaleCommon Stock | 2,500 | $5.78 | $14,445.00 |
DisclosureSEC source: 0001209191-22-035643 · doc4.xml · nonDerivative · entry 1 Ridley Irina · CIK 0001855591 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,139 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.55 to $5.93, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| April 22, 2022 Filed Feb 25, 2025 23:31 UTC |
Morrell MarthaCHIEF MEDICAL OFFICER
|
Tax withholdingCommon Stock | 926 | $8.32 | $7,704.32 |
DisclosureSEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,836 Read SEC document |
| April 22, 2022 Filed Feb 25, 2025 17:41 UTC |
Kuhn RebeccaChief Financial Officer
|
Tax withholdingCommon Stock | 718 | $8.32 | $5,973.76 |
DisclosureSEC source: 0001415889-25-005559 · form4-02252025_100218.xml · nonDerivative · entry 1 Kuhn Rebecca · CIK 0001855659 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,486 Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 16:43 UTC |
Favet MichaelDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 310,160 | $0.00 Strike: $8.10 | $0.00 |
DisclosureSEC source: 0001209191-22-017119 · doc4.xml · derivative · entry 2 Favet Michael · CIK 0001855656 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,160 Underlying: Common Stock · 310,160 shares Expires 2032-03-07 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on March 8, 2023. The remaining shares subject to the option vest in thirty six (36) equal consecutive monthly installments thereafter. The option is early exercisable. Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 16:43 UTC |
Favet MichaelDirector · Chief Executive Officer
|
GrantCommon Stock | 155,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017119 · doc4.xml · nonDerivative · entry 1 Favet Michael · CIK 0001855656 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,080 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on March 8, 2023 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 20:07 UTC |
Ridley IrinaGeneral Counsel and Secretary
|
GrantStock Option (Right to Buy) · Derivative | 83,530 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001209191-22-016877 · doc4.xml · derivative · entry 2 Ridley Irina · CIK 0001855591 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,530 Underlying: Common Stock · 83,530 shares Expires 2032-03-02 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on March 3, 2023. The remaining shares subject to the option vest in thirty six (36) equal consecutive monthly installments thereafter. The option is early exercisable. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 20:07 UTC |
Ridley IrinaGeneral Counsel and Secretary
|
GrantCommon Stock | 56,987 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016877 · doc4.xml · nonDerivative · entry 1 Ridley Irina · CIK 0001855591 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,639 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on March 3, 2023 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.